[The lipid model in hemodialyzed patients].
In the context of metabolic alteration in dialysis patients the Authors have studied the characteristics, incidence, pathogenesis, effect of dialysis, atherogenic risk and therapeutic approach to hyperlipemia in hemodialysis patients. Hypertriglyceridemia secondary to reduced lipolytic activity is the most frequent alteration observed in hemodialytic patients (36.7% of cases). In addition, hemodialysis reduces the levels of lipoprotein in the blood whereas the atherogenic role of hyperlipemia does not appear to be as important as that of arterial hypertension and smoking. Simvastatin breaks down the lipidic fractions which are involved in atherogenesis and coronary cardiopathy, thus acting as a valuable prevention against cardiovascular involvement in dialysis.
Navino
C
C
Divisione di Nefrologia e Dialisi, Ospedale Maggiore della Carità, Novara.
Zamboni
G
G
Barbè
M C
MC
Guida
G E
GE
Ruva
C E
CE
De Leo
M
M
Cusaro
C
C
Pecora
S
S
Chiarinotti
D
D
Verzetti
G
G
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000209:etiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D015994:Incidence; D008066:Lipolysis; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012307:Risk Factors; D019821:Simvastatin; D012907:Smoking; D014511:Uremia / Q000150:complications / Q000628:therapy
D008074:Lipoproteins; D008148:Lovastatin; D019821:Simvastatin
Il modello lipidico negli emodializzati.